Drug Profile
Azeliragon - vTv Therapeutics
Alternative Names: PF-04494700; PF-4494700; TTP-488Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator TransTech Pharma
- Developer Baptist Health South Florida; Cantex Pharmaceuticals; Pfizer; TransTech Pharma; vTv Therapeutics LLC
- Class Antidementias; Antihyperglycaemics; Antineoplastics; Chlorobenzenes; Diethylamines; Imidazoles; Phenyl ethers; Propylamines; Small molecules
- Mechanism of Action Advanced glycosylation end product receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III COVID 2019 infections
- Phase II Breast cancer; Glioblastoma; Pancreatic cancer
- Phase I/II Brain metastases
- Phase I Cancer; Cancer pain; Lung cancer
- Preclinical Triple negative breast cancer; Type 1 diabetes mellitus
- Discontinued Alzheimer's disease; Diabetic nephropathies
Most Recent Events
- 05 Sep 2023 Phase-I/II clinical trials in Glioblastoma (Combination therapy, First-line therapy, Newly diagnosed) in Spain (PO) (NCT05635734)
- 28 Aug 2023 Phase-I/II clinical trials in Brain metastases (Combination therapy) in USA (PO) (NCT05789589)
- 28 Aug 2023 Phase-II clinical trials in Glioblastoma (Newly diagnosed) in USA (PO, Capsule) (NCT05986851)